Non-small-cell Lung Cancer Clinical Trial
Official title:
Effect of Exercise Training on Angiogenesis and Cachexia in Lung Cancer Patients
Verified date | November 2011 |
Source | National Taiwan University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | Taiwan: Department of Health |
Study type | Interventional |
Cancer is one of the leading health issues in this country and worldwide. Angiogenesis is an
essential process for tumoral growth and metastasis. This process is dependent on the
balance between angiogenic factors and antiangiogenic factors. Muscle wasting has been
associated with myostatin overexpression in cancer. Exercise training can depress tumor
growth and suppress myostatin expression, and enhance skeletal muscle angiogenesis in
healthy people and some animal studies. The purpose of this study is mainly to investigate
the effects of exercise training on
1. circulating VEGF-A
2. muscle growth and function
3. Myostatin
Status | Completed |
Enrollment | 60 |
Est. completion date | August 2012 |
Est. primary completion date | August 2011 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 40 Years to 75 Years |
Eligibility |
Inclusion Criteria: - Age 40-75 years - Advanced NSCLC - Eastern Cooperative Oncology Group performance status of 0 or 1 - Targeted therapy for at least 8 weeks - Stable condition Exclusion Criteria: - Severe metastasis, cardiopulmonary or musculoskeletal conditions may affect participation in exercise - Do not understand the verbal or written instructions |
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Taiwan | National Taiwan University Hospital | Taipei City |
Lead Sponsor | Collaborator |
---|---|
National Taiwan University Hospital | National Science Council, Taiwan |
Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Exercise capacity | Maximal oxygen consumption with Vmax229 Vastus lateral muscle oxygenation with NIRS | 8 weeks after the start of the intervention | No |
Secondary | Imaging of muscle | Measured by MRS | 8 weeks and 16 weeks after the start of the intervention | No |
Secondary | Analysis of venous blood sample | Analysis of circulating VEGF-A and myostatin | 8 weeks andd 16 weeks after the start of the intervention | No |
Secondary | Quality of life | Measured by questionnaire | baseline, 8 weeks, 16 weeks | No |
Secondary | Exercise capacity | Maximal oxygen consumption with Vmax229 Vastus lateral muscle oxygenation with NIRS | 16 weeks after the start of the intervention | No |
Secondary | Muscle function | Isokinetic muscle strength and endurance with Biodex | 8 weeks and 16 weeks after the start of the intervention | No |
Secondary | Physical activity | Measured with 7-day recall questionnaire | 8 weeks andd 16 weeks after the start of the intervention | No |
Secondary | Dietary intake | Measured with 24-hour recall questionnaire | 8 weeks andd 16 weeks after the start of the intervention | No |
Secondary | Body composition | Body mass index calculated with body weight and height % body fat abd free-fat mass with BIA |
8 weeks andd 16 weeks after the start of the intervention | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02495233 -
A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)
|
Phase 1/Phase 2 | |
Withdrawn |
NCT02672358 -
Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLC
|
Phase 2 | |
Recruiting |
NCT05815472 -
Advanced Patient Monitoring and A.I. Supported Outcomes Assessment in Lung Cancer Using Internet of Things Technologies (A.I. - APALITT)
|
N/A | |
Not yet recruiting |
NCT05900219 -
Efficacy and Safety of HL-085 Combined With Vemurafenib in BRAF V600E Patients With Non-small Cell Lung Cancer: a Phase II Clinical Study
|
Phase 2 | |
Not yet recruiting |
NCT04560244 -
A Trial of SHR1701 Combined With Radiotherapy for Metastatic Non-small Cell Lung Cancer Failure After First-line Treatment
|
Phase 2 | |
Not yet recruiting |
NCT02907606 -
Urinary Circulating Tumor DNA Detection in Non-small Cell Lung Cancer: a Prospective Study
|
N/A | |
Completed |
NCT01924416 -
Lung Cancer Information Study (LCIS-R01)
|
N/A | |
Completed |
NCT00831454 -
Identification of EGFR-TKIs Sensitivity or Resistance Markers in NSCLC May Help in Optimal Patient Selection
|
N/A | |
Completed |
NCT00363766 -
Study of LY573636-Sodium in Patients With Metastatic Non-Small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT00913705 -
Neoadjuvant or Adjuvant Chemotherapy in Patients With Operable Non-small-cell Lung Cancer
|
Phase 3 | |
Completed |
NCT01383135 -
Biodistribution and Safety of the PET Probes [18F]FPRGD2 and [18F]FPPRGD2
|
Early Phase 1 | |
Completed |
NCT01124864 -
A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy.
|
Phase 2 | |
Completed |
NCT00049998 -
Oral Topotecan Versus Intravenous Docetaxel In Pretreated, Advanced Non-Small Cell Lung Cancer
|
Phase 3 | |
Terminated |
NCT05061537 -
Study of PF-07263689 in Participants With Selected Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT03320044 -
Early Diagnosis of Small Pulmonary Nodules by Multi-omics Sequencing
|
||
Recruiting |
NCT04895930 -
Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC
|
Phase 2 | |
Recruiting |
NCT03267654 -
Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance
|
Phase 2 | |
Recruiting |
NCT04401059 -
Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC:Prospective Study
|
Phase 4 | |
Completed |
NCT02965391 -
Dynamic Changes of Circulating Tumor DNA in Surgical Lung Cancer Patients
|
||
Not yet recruiting |
NCT02930954 -
Gefitinib Combined With Chemotherapy or Antiangiogensis in Patients With Bim Deletion or Low EGFR Mutation Abundance
|
Phase 2 |